San Diego Convention Center
CA
On Thursday, June 6, 2024, Morrison Foerster partner Stacy Amin will moderate a panel at the BIO International Convention.
The US Supreme Court and the End of Scientific Deference?
June 6, 2024; 9:00 – 10:00 a.m. PDT; Session Room 31C
The U.S. Supreme Court has been chipping away at the power of administrative agencies in recent years. In a pair of significant cases before the Court this year, Loper Bright Enterprises v. Raimondo and Relentless, Inc. v. Department of Commerce, the Court is widely expected to overturn or narrow the longstanding practice (called “Chevron deference”) of courts deferring to reasonable agency rulemakings. This panel will explore the profound impact that the loss of Chevron deference could have on the life sciences industry. The panel will also discuss the challenges to FDA’s decades-old approval of the abortion drug mifepristone, which raises numerous questions about the scope of FDA’s authority and the extent to which courts will defer to scientific expertise. Lastly, the panel will explore how these cases could impact investment decisions, R&D efforts, and the competitive marketplace, as well as steps that the industry could take in the aftermath.
Moderator:
Stacy Amin, Partner, Morrison Foerster
Panelists:
Vanessa K. Burrows, Partner, Simpson Thacher & Bartlett LLP
Judith Haron, Assistant General Counsel, PhRMA
Zach Howe, Assistant U.S. Attorney, Southern District of California